Inflammatory bowel disease: The asthma of the intestine?

Inflammatory Bowel Diseases

Volumn 2, Issue 2, 1996, Pages 122-132

  Eliakim, R ^a   Rachmilewitz, D ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 8644241150     PISSN: 10780998     EISSN: None     Source Type: Journal    
DOI: 10.1002/ibd.3780020210     Document Type: Review

References (157)

1. McFadden ER, Gilbert IA. Asthma. N Engl J Med 1992; 327:1928-37.
2. Kay AB. Asthma and inflammation. J Allergy Clin Immunol 1991;87:893-910.
3. Houston JC, De Navasquez S, Trounce JR. A clinical and pathological study of fatal cases of status asthmaticus. Thorax 1953;8:207-13.
4. Dunnill MS. The pathology of asthma with special reference to change in bronchial mucosa. J Clin Pathol 1960;13: 27-33.
5. Dunnill MS, Massarella GR, Anderson JA. A comparison of the quantitative anatomy of the bronchi in normal subjects, in status asthmaticus, in chronic bronchitis and in emphysema. Thorax 1969;24:176-9.
6. Eliakim R, Rachmilewitz D. Potential mediators in inflammatory bowel disease. Gastroenlerol Int 1992;5:48-56.
7. MacDermott RP, Stenson WF. The immunology of idiopathic inflammatory bowel disease. Hosp Proc 1986;1:97-116.
8. Campieri M, Lanfranchi GA, Bozzochi G. Prostaglandins, indomethacin and ulcerative colitis. Gastroenterology 1980;78:193.
9. 2. Dig Dis Sci 1983;28:807-11.
10. Parker CW. Mediators: release and function. In: Paul WE, ed. Fundamental immunology. New York: Raven Press, 1984:697-750.
11. Wardlaw AJ, Dunnette S, Gleich GJ, Collins JV, Kay AB. Eosinophils and mast cells in bronchoalveolar lavage in mild asthma: relationship to bronchial hyper-reactivity. Am Rev Respir Dis 1988;137:62-9.
12. 2 and other bronchoconstricting prostaglandins in the airways of subjects with mild asthma. Am Rev Respir Dis 1990;142: 126-32.
13. Kaliner M. Asthma and mast cell activation. J Allergy Clin Immunol 1989;83:510-20.
14. Casale TB, Wood D, Richerson HB, Zehr B, Zavala D, Hunnighake GW. Direct evidence of a role of mast cells in the pathogenesis of antigen-induced bronchoconstriction. J Clin Invest 1987;80:1507-11.
15. Kirsner JD, Shorter RG. Recent developments in non-specific inflammatory bowel disease. N Engl J Med 1982; 306:775-85, 837-48.
16. Fox CC, Lichtenstein LM, Roche JK. Intestinal mast cell responses in idiopathic inflammatory bowel disease: histamine release from human intestinal mast cells in response to gut epithelial proteins. Dig Dis Sci 1993;38:1105-12.
17. Knutson L, Ahrenstedt Ö, Odlind B, Hällgren R. The jejunal secretion of histamine is increased in active Crohn's disease. Gastroenterology 1990;98:849-54.
18. Fox CC, Lazenby AJ, Moore WC, Yardley JH, Bayless TM, Lichtenstein LM. Enhancement of human intestinal mast cell mediator release in active ulcerative colitis. Gastroenterology 1990;99:119-24.
19. King T, Biddle W, Bhatia P, Moore J, Miner PB Jr. Colonic mucosal mast cell distribution at line of demarcation of active ulcerative colitis. Dig Dis Sci 1992;37:490-5.
20. Binder V, Huidberg E. Histamine content of rectal mucosa in ulcerative colitis. Gut 1967;8:24-8.
21. Fox CC, Moore WC, Bayless TM, Lichtenstein LM. Enhanced intestinal mast cell histamine release in idiopathic inflammatory bowel disease. In: MacDermott RP, ed. Inflammatory bowel disease: current status and future approach. Amsterdam: Elsevier Scientific, 1988:355-9.
22. Ghiara P, Boraschi D, Villa L, Scapigliati G, Toddei C, Tagliabne A. In vitro generated mast cells express natural cytotoxicity against tumor cells. Immunology 1985;55:317-24.
23. Farram E, Nelson DS. Mouse mast cells as anti-tumor effector cells. Cell Immunol 1980;55:294-301.
24. Henderson WR, Chi EY, Jong EC, Klebanoff SJ. Mast cell mediated tumor cell cytotoxicity. Role of peroxidase system. J Exp Med 1981;153:520-33.
25. Movat HZ. The inflammatory reaction. Amsterdam: Elsevier Scientific, 1988.
26. Falkman J. How is blood vessel growth regulated in normal and neoplastic tissue? Cancer Res 1988;46:467-73.
27. 4 in patients with or without Crohn's disease. Gastroenterology 1989;96:A527.
28. Beer DJ, Rocklin RE. Histamine induced suppressor cell activity. J Allergy Clin Immunol 1984;73:439-52.
29. Djukanovic R, Wilson JW, Brittens KM, et al. Effect of inhaled corticosteroids on airway inflammation and symptoms of asthma. Am Rev Respir Dis 1992;145:669-74.
30. Jeffrey PK, Godfrey RW, Adelroth E, Nelson F, Rogers A, Johansson SA. Effects of treatment on airway inflammation and thickening of basement membrane reticular collagen in asthma: a quantitative light and electron microscopic study. Am Rev Respir Dis 1992;145:890-99.
31. Schleimer RP. The mechanism of anti-inflammatory steroid action in allergic disease. Annu Rev Pharmacol Toxicol 1985;25:381-412.
32. Goldsmith P, McGarity B, Walls AF, Church MK, Millward-Sadler GH, Robertson DAF. Corticosteroid treatment reduces mast cell numbers in inflammatory bowel disease. Dig Dis Sci 1990;35:1409-13.
33. Befus D, Dyck N, Goodacre R, Bienenstock J. Mast cells from the human intestinal lamina propria: isolation, histochemical subtypes and functional characterization. J Immunol 1987;138:2604-8.
34. Buckell NA, Gould SR, Day DW, Lennard-Jones JE, Edwards AM. Controlled trial of disodium cromoglycate in chronic persistent ulcerative colitis. Gut 1978;19:1140-3.
35. Willoughby CP, Heyworth MF, Piris J, Truelove SC. Comparison of disodium cromoglycate and sulphasalazine as maintenance therapy for ulcerative colitis. Lancet 1979;1: 119-22.
36. Eliakim R, Karmeli F, Okon E, Rachmilewitz D. Ketotifen effectively prevents mucosal damage in experimental colitis. Gut 1992;33:1498-503.
37. Pothoulakis C, Karmeli F, Kelly CP, Eliakim R, Joshi MA, O'Keane CCJ, Castagliuolo I, LaMont JT, Rachmilewitz D. Ketotifen inhibits Glostridium difficile toxin A-induced enteritis in rat ileum. Gastroenterology 1993;105:701-7.
38. Durham SR, Kay AB. Eosinophils, bronchial hyperreactivity and late-phase asthmatic reactions. Clin Allergy 1985;15:1411-8.
39. Djukanovic R, Roche WR, Wilson SW, et al. Mucosal inflammation in asthma. Am Rev Respir Dis 1990;142:434-57.
40. Barnes PJ. Neuropeptides and asthma. Am Rev Respir Dis 1991;143:528-32.
41. 4. Proc Natl Acad Sci USA 1983;80:7626-30.
42. Lee TC, Lenihan DJ, Malone B, Ruddy LL, Wasserman SI. Increased biosynthesis of platelet activating factor in activated human eosinophils. J Biol Chem 1984;259:5520-30.
43. Solopato M, Mattoso VL, Fasoli A, Mattoli S. A bronchial epithelial cell-derived factor in asthma that promotes eosinophil activation and survival as GM-CSF. Am J Physiol 1991;260:L530-8.
44. Sarin SK, Malhotra V, Gupta SS, Karel A, Gaur SK, Anad BS. Significance of eosinophil and mast cell counts in rectal mucosa in ulcerative colitis. Dig Dis Sci 1987;32:363-67.
45. Berstad A, Børkje B, Riedel B, Elsayed S, Berstad A. Increased fecal eosinophil cationic protein in inflammatory bowel disease. Hepatogastroenterology 1993;40:276-8.
46. Levy AM, Sandborn WJ, Tremaine WJ, Zinsmeister AR, Gleich GJ. Eosinophil derived neurotoxin (EDN) concentrations are elevated in gut lavage fluid of patients with inflammatory bowel disease [Abstract]. Immunol Microbiol Inflam Disord 1995;16:A861.
47. Dvorak AM, Onderdonk AB, McLeod RS, et al. Ultrastructural identification of exocytosis of granules from human gut eosinophils in vivo. Int Arch Allergy Immunol 1993;102:33-45.
48. Review. The eosinophil in inflammatory bowel disease. Scand J Gastroenterol 1991;26:1217-24.
49. Barnes PJ. Neural control of human airways in health and disease. Am Rev Respir Dis 1986;134:1289-314.
50. Lundberg JM, Saria A, Brodin E, Russels S, Falkers R. A substance P antagonist inhibits vagally induced increase in vascular permeability and bronchial smooth muscle contraction in the guinea-pig. Proc Natl Acad Sci USA 1983; 80:1120-4.
51. Lundberg JM, Saria A, Lundblad L, et al. Bioactive peptides in capsaicin-sensitive C-fiber afferents of the airways: functional and pathophysiological implications. In: Kaliner MA, Barnes PJ, eds. The airways: neural control in health and disease. New York: Marcel Dekker, 1987:417-45.
52. Lundberg JM, Saria A. Capsaicin induced desensitization of the airway mucosa to cigarette smoke, mechanical and chemical irritants. Nature 1983;302:251-3.
53. Lundberg JM, Martling CR, Sarid A. Substance P and cap-saicin-induced contraction of human bronchi. Acta Physiol Scand 1983;119:49-53.
54. Fuller RW, Dixon CMS, Barnes PJ. The bronchoconstrictor response to inhaled capsaicin in humans. J Appl Physiol 1985;85:1080-4.
55. Eliakim R, Rachmilewitz D. Inflammatory mediators and the pathogenesis of inflammatory bowel disease. Ital J Gastroenterol 1992;24:361-8.
56. Hurst SM, Stanisz AM, Sharkey KA, Collins SM. Interleukin 1β-induced increase in substance P in rat myenteric plexus. Gastroenterology 1993;105:1754-60.
57. Mayer EA, Raybould H, Koelbel C. Neuropeptides, inflammation and motility. Dig Dis Sci 1988;33:71S-7S.
58. Bartho L, Holzer P. Search for a physiological role of substance P in gastrointestinal motility. Neuroscience 1985;16: 1-32.
59. Llewellyn-Smith IJ, Furness JB, Murphy R, O'Brien PE, Costa M. Substance P-containing nerves in the human small intestine. Gastroenterology 1984;86:421-35.
60. Mantyh CR, Vigna SR, Bollinger RR, Mantyh PW, Maggio JE, Pappas TN. Differential expression of substance P receptors in patients with Crohn's disease and ulcerative colitis. Gastroenterology 1995;109:850-60.
61. Gates T, Zimmerman R, Mantyh C, Vigna S, Nelton M, Passaro E Jr, Maggio J, Kruger L, Mantyh P. Receptor binding sites for substance P are ectopically expressed in high concentrations by arterioles, venules and lymph nodules in surgical specimens obtained from patients with inflammatory bowel disease. In: MacDermott RP, ed. Inflammatory bowel disease: current status and future approach. Amsterdam: Elsevier Scientific, 1988:37-42.
62. Ruff MR, Wahl SM, Pert CB. Substance P receptor-mediated chemotaxis of human monocytes. Peptides 1985; 6:107S-11S.
63. Marasco WA, Showell HJ, Becker EL. Substance P binds to the formylpeptide chemotaxis receptor on the rabbit neutrophil. Biochem Biophys Res Commun 1981;99:1065-72.
64. Foreman JC, Piotrowski W. Peptides and histamine release. J Allergy Clin Immunol 1984;74:127-31.
65. Stead RH, Tomioka M, Riddell RH, Bienenstock J. Substance P and/or calcitonin gene related peptide are present in sub-epithelial enteric nerves apposed to intestinal mucosal mast cells. In: MacDermott RP, ed. Inflammatory bowel disease: current status and future approach. Amsterdam: Elsevier Scientific, 1988:43-8.
66. Mazumdar S, Das KM. Immunocytochemical localization of vasoactive intestinal peptide and substance P in the colon from normal subjects and patients with inflammatory bowel disease. Am J Gastroenterol 1992;87:176.
67. Goldin E, Karmeli F, Selinger Z, Rachmilewitz D. Colonic substance P levels are increased in ulcerative colitis and decreased in chronic severe constipation. Dig Dis Sci 1989; 34:754-7.
68. Giladi E, Karmeli F, Gozes I, Rachmilewitz D. Enhanced substance P and VIP expression in experimental colitis. Gastroenterology 1996;106:A687.
69. Bernstein CN, Robert ME, Eysselein VE. Rectal substance P concentrations are increased in ulcerative colitis but not in Crohn's disease. Am J Gastroenterol 1993;88:908.
70. Barnes PJ, Dixon CMS. The effect of inhaled VIP on bronchial hyper-reactivity in man. Am Rev Respir Dis 1984;130: 162-6.
71. Boirivant M, Fais S, Annibale B, Agostini D, Delle Fave G, Pallone G. Vasoactive intestinal polypeptide modulates the in vitro immunoglobulin A production by intestinal lamina propria lymphocytes. Gastroenterology 1994;106:576-82.
72. Kubota Y, Petras RE, Ottaway CA, Tubbs RR, Farmer RG, Fiocchi C. Colonic vasoactive intestinal peptide nerves in inflammatory bowel disease. Gastroenterology 1992;102:1242-51.
73. Koch TR, Carney JA, Go VLW. Distribution and quantitalion of gut peptides in normal colon and ulcerative colitis (UC). Gastroenterology 1984;86:1139A.
74. Koch TR, Carney JA, Go VLW, Szurszewski JH. Altered inhibitory innervation of circular smooth muscle in Crohn's colitis: association with decreased vasoactive intestinal polypeptide levels. Gastroenterology 1990;98:1437-44.
75. Koch TR, Carney JA, Go VLW. Gut regulating peptides in Crohn's ileitis (CI) and colitis (CC). Gastroenterology 1984; 86:1139A.
76. Kishimoto S, Kobayashi H, Shimizu S, Haruma K, Tamaru T, Kajiyama G, Miyoshi A. Changes of colonic vasoactive intestinal peptide and cholinergic activity in rats with chemical colitis. Dig Dis Sci 1992;37:1729-37.
77. Ponchon J, Jourdan G, Descos L, Chayvialle JA. Mucosal concentrations of vasoactive intestinal peptide, somatostatin and substance P in Crohn's disease and ulcerative colitis. Gastroenterology 1984;86:1211A.
78. Duffy LC, Zielezny MA, Piepenhoff-Talty M, et al. Vasoactive intestinal peptide as a laboratory supplement to clinical activity index in inflammatory bowel disease. Dig Dis Sci 1989;34:1528-35.
79. Reubi JC, Horisberger U, Waser B, Gebbers JO, Laissue J. Preferential location of somatostatin receptors in germinal centers of human gut lymphoid tissue. Gastroenterology 1992;103:1207-14.
80. Eliakim R, Karmeli F, Okon E, Rachmilewitz D. Octreotide effectively prevents mucosal damage in experimental colitis. Gut 1993;34:264-9.
81. Koch TR, Carney JA, Morris VA, Go VLW. Somatostatin in the idiopathic inflammatory bowel disease. Dis Colon Rectum 1988;37:798-803.
82. Dharmsathaphorn K, Sherwin RS, Dobbins JW. Somatostatin inhibits fluid secretion in the rat jejunum. Gastroenterology 1980;78:1554-8.
83. Dharmsathaphorn K, Binder HJ, Dobbins JW, Lee L. Somatostatin stimulates sodium and chloride absorption in the rabbit ileum. Gastroenterology 1980;78:1559-65.
84. Ahonen A, Kyosola K, Pentilla O. Enterochromaffin cells and macrophages in ulcerative colitis and irritable colon. Ann Clin Res 1976;8:1-7.
85. Kyosola K, Pentilla O, Salaspuro M. Rectal mucosal adrenergic innervation and enterochromaffin cells in ulcerative colitis and irritable colon. Scand J Gastroenterol 1977;72:363-7.
86. Bishop AE, Polak JM, Brant MG, Bloom SR, Hamilton S. Abnormalities of vasoactive intestinal polypeptide-containing nerves in Crohn's disease. Gastroenterology 1980;79:853-60.
87. Watanabe T, Kubota Y, Sawada T, Muto T. Distribution and quantification of somatostatin in inflammatory disease. Dis Colon Rectum 1992;35:488-94.
88. Reubi JC, Mazzucchelli L, Laissue JA. Intestinal vessels express a high density of somatostatin receptors in human inflammatory bowel disease. Gastroenterology 1994;106: 951-9.
89. Eliakim R, Karmeli F, Rachmilewitz D. Decreased somatostatin (SS) generation by cultured colonic mucosa in active ulcerative colitis (UC). Gastroenterology 1991;100:578A.
90. Sharon P, Stenson WF. Enhanced synthesis of leukotriene by colonic mucosa in inflammatory bowel disease. Gastroenterology 1984;86:453-60.
91. Bayer G, Maier KE, Klotz V. Enhanced synthesis of hydroxyeicosatetraenoic acids by colonic mucosa in chronic inflammatory bowel disease. In: MacDermott RP, ed. Inflammatory bowel disease: current status and future approach. Amsterdam: Elsevier Scientific, 1988:291-6.
92. 4. Dig Dis Sci 1987;32:1380-8.
93. Lauristen K, Lainsen LS, Bokhave K, Rask-Madsen J. Effects of systemic prednisolone on arachidonic acid and metabolites determined by equilibrium in vivo dialysis of rectum in severe relapsing ulcerative colitis. Gastroenterology 1985;88:1465A.
94. Peskar BM, Dreyling KW, Hoppe U, Schaarschmidt K, Goebell H, Peskar BA. Formation of sulfidopeptide-leukotrienes (SP-LT) in normal colonic tissue, colonic carcinoma and Crohn's disease. Gastroenterology 1985;88: 1537A.
95. Wallace JL. 5-Lipoxygenase: a rational target for therapy of inflammatory bowel disease? Trends Pharmacol Sci 1990;17:51-3.
96. Wallace JL, MacNaughton WK, Morris GP, Beck PL. Inhibition of leukotriene synthesis markedly accelerates healing in a rat model of inflammatory bowel disease. Gastroenterology 1989;96:29-36.
97. Empey LR, Garg ML. Eicosapentoic acid (fish oil)-enriched diet is protective in rat experimental colitis. Gastroenterology 1989;96:A682.
98. Stenson WF, Cort D, Rodgers J, Burakoff R, Deschryver-Kecskemeti K, Garmlich TL, Beeken W. Dietary supplementation with fish oil in ulcerative colitis. Ann Intern Med 1992;116:609-14.
99. Hawthorne AB, Daneshmend TK, Hawkey CJ, Belluzi A, Everitt JJ, Holmes GK, et al. Treatment of ulcerative colitis with fish oil supplementation: a prospective 12-month randomized trial. Gut 1992;33:922-8.
100. Hawkey CJ, Gassull M, Lauristen K, Martin F, Omorian C, Rask-Madsen J, et al. Efficacy of zileuton, a 5-lipoxygenase inhibitor, in the maintenance of remission in patients with ulcerative colitis. Gastroenterology 1994;106:A751.
101. Benveniste J, Henson PM, Cochrane CG. Leukocyte-dependent histamine release from rabbit platelets: the role of IgE basophils and platelet activating factor. J Exp Med 1972;136:1356-77.
102. Latner GZ, Lynch JM, Betz SJ, Henson PM. Human neutrophil-derived platelet-activating factor. J Immunol 1980; 124:676-84.
103. Mencia-Huerta JM, Benveniste J. Platelet activating factor and macrophages. I. Evidence for the release from rat and mouse peritoneal macrophages and not from mastocytes. Eur J Immunol 1979;9:409-15.
104. Mencia-Huerta JM, Lewis R, Razin E, Austen KF. Antigen-initiated release of platelet-activating factor (PAF-acether) from mouse bone-marrow derived mast cells sensitized with monoclonal IgE. J Immunol 1983;130:2958-64.
105. Jouvin-Marche E, Ninio E, Beaurain G, Tence M, Niaudet P, Benveniste J. Biosynthesis of PAF-acether (platelet-activating factor). VII. Precursors of PAF-acether and acetyltransferase activity in human leucocytes. J Immunol 1984;133:892-8.
106. Henson PM. Cellular sources of platelet activating factor. In: Russo-Marie F, Vargaftig BB, Benveniste J, eds. Pharmacology of inflammation and allergy, vol 100. Paris: Publications INSERM, 1981:63-81.
107. Spence DP, Johnston SL, Calverley PM, Dhillon P, Higgins C, Ramhamadany E, Turner S, Winning A, Winter J, Hoigate ST. The effect of the orally active platelet activating factor antagonist WEB 2086 in the treatment of asthma. Am J Respir Crit Care Med 1994;149:1142-8.
108. Takizawa H. Eosinophils in immediate allergic reactions. Nippon Rinsho 1993;51:664-8.
109. Kuitert LM, Hui KP, Uthayarkumar S, Burke W, Newland AC, Uden S, Barnes NC. Effect of platelet activating factor antagonist UK-74,505 on the early and late response to allergen. Am Rev Respir Dis 1993;147:82-6.
110. Stenson WF. Platelet activating factor and inflammatory bowel disease. Gastroenterology 1988;95:416-21.
111. Eliakim R, Karmeli F, Razin E, Rachmilewitz D. Role of platelet activating factor in ulcerative colitis. Enhanced production during active disease and inhibition by sulfasalazine and prednisolone. Gastroenterology 1988;95: 1167-72.
112. Wallace JL. Release of platelet activating factor (PAF) and accelerated healing induced by a PAF antagonist in an animal model of chronic colitis. Can J Physiol Pharmacol 1988;66:422-5.
113. Hamid Q, Azzawi M, Ying S, et al. Expression of mRNA for interleukin-5 in mucosal bronchial biopsies from asthma. J Clin Invest 1991;87:1541-6.
114. Azzawi M, Bradely B, Jeffrey PK, et al. Identification of activated T lymphocytes and eosinophils in bronchial biopsies in stable atopic asthma. Am Rev Respir Dis 1990;142: 1407-13.
115. Cominelli F, Kam L. Inflammatory mediators in inflammatory bowel disease. Opinions Gastroenterol 1993;91:534-43.
116. Simon PL, West GA, Rachmilewitz D, Fiocchi C. Investigations of interleukin-1 (IL-1) activity in intestinal mucosa of Crohn's disease (CD) and ulcerative colitis (UC) patients. Gastroenterology 1989;96:473A.
117. Suzuki Y, Tobin A, Quinn D, Whelan A, Mokin CO. Interleukin-1 in inflammatory bowel disease. Gastroenterology 1989;96:498A.
118. Kusugami I, Youngman KR, West GA, Fiocchi C. Intestinal immune reactivity to interleukin-2 differs among Crohn's disease, ulcerative colitis and controls. Gastroenterology 1989;97:1-9.
119. Overview of approaches to asthma therapy. In: Guidelines for the diagnosis and management of asthma: National Asthma Education Program Expert Panel Report. NIH publication no. 91-3042. Bethesda: Department of Health and Human Services, 1991:35-43.
120. Podolsky DK. Inflammatory bowel disease. N Engl J Med 1991;325:1008-15.
121. Lennard-Jones JE. Towards optimal use of corticosteroids in ulcerative colitis and Crohn's disease. Gut 1983;24:177-81.
122. Meyers S, Sachar D, Goldberg JD, Janowitz HD. Corticotropin versus hydrocortisone in the intravenous treatment of ulcerative colitis: a prospective randomized, double-blind clinical trial. Gastroenterology 1983;85:351-7.
123. Ruddell WSJ, Dickinson RJ, Dixon MF, Axon ATR. Treatment of distal ulcerative colitis (proctosigmoiditis) in relapse: comparison of hydrocortisone enemas and rectal hydrocortisone. Gut 1980;21:885-9.
124. Kumana CR, Seaton T, Meghji M, Castelli M, Benzon R, Sivakumaran T. Bedemethasone dipropionate enemas for treating inflammatory bowel disease without producing Cushing's syndrome or hypothalamic pituitary adrenal suppression. Lancet 1982;1:579-33.
125. Debinski HS, Kamm MA. Novel drug therapies in inflammatory bowel disease. Eur J Gastroenterol Hepatol 1995; 7:169-81.
126. Greenberg GR, Feagan BG, Martin F, Sutherland L, Thomson ABR, Williams CN, Nilsson LG, Persson T. Oral budesonide for active Crohn's disease. N Engl J Med 1994; 331:836-11.
127. Rutgeerts P, Lofberg R, Malchow H, Lamers C, Olaison G, Jewell D, Daniellson A, Goebell H, et al. A comparison of budesonide with prednisolone for active Crohn's disease. N Engl J Med 1994;331:842-5.
128. Kanzow G, Nowak D, Magnussen H. Short term effect of methotrexate in severe steroid-dependent asthma [Abstract]. Lung 1995;173:223-31.
129. Stanziola A, Sofia M, Mormile M, Molino A, Carratu L. Long-term treatment with methotrexate in patients with corticosteroid-dependent bronchial asthma [Abstract]. Monaldi Arch Chest Dis 1995;50:109-13.
130. Shiner RJ, Katz I, Shulimzon T, Silkoff P, Benzaray S. Methotrexate in steroid-dependent asthma: long-term results [Abstract]. Allergy 1994;49:565-8.
131. Stewart GE II, Diaz JD, Lockey RF, Seleznick MJ, Trudeau WL, Ledford DK. Comparison of oral pulse methotrexate with placebo in the treatment of severe glucocorticosteroid-dependent asthma [Abstract]. J Allergy Clin Immunol 1994;949:482-9.
132. Cott GR. Perspectives on methotrexate in the treatment of asthma [Editorial;comment]. Chest 1994;105:649-50.
133. Coffey MJ, Sanders G, Eschenbacher WL, Tsien A, Ramesh S, Weber RW, Toews GB, McCune WJ. The role of methotrexate in the management of steroid-dependent asthma [Abstract]. Chest 1994;105:117-21.
134. Bardin PG, Fraenkel DJ, Beasley RW. Methotrexate in asthma: a safety perspective [Review]. Drug Safety 1993; 9:151-5.
135. Yntema JL, Walker C, Aalbers R. Methotrexate in the treatment of severe asthma [Review]. Respir Med 1993;87 (suppl B):57-60.
136. Trigg CJ, Davies RJ. Comparison of methotrexate 30 mg per week with placebo in chronic steroid-dependent asthma: a 12-week double-blind, cross-over study [Abstract]. Respir Med 1993;87:211-6.
137. Stempel DA, Lammert J, Mullarkey MF. Use of methotrexate in the treatment of steroid-dependent adolescent asthmatics [Abstract]. Ann Allergy 1991;67:346-8.
138. Dyer PD, Vaughan TR, Weber RW. Methotrexate in the treatment of steroid-dependent asthma [Abstract]. J Allergy Clin Immunol 1991;88:208-12.
139. Erzurum SC, Leff JA, Cochran JE, Ackerson LM, Szefler SJ, Martin RJ, Cott GR. Lack of benefit of methotrexate in severe steroid-dependent asthma. A double-blind, placebo-controlled study [Abstract]. Ann Intern Med 1991;114:353-60.
140. Mullarkey MF, Blumenstein BA, Andrade WP, Bailey GA, Olaison I, Wetzel CE. Methotrexate in the treatment of corticosteroid-dependent asthma: a double-blind crossover study. N Engl J Med 1988;318:603-7.
141. Dyer PD, Vaughan TR, Weber RW. Methotrexate in the treatment of steroid-dependent asthma. J Allergy Clin Immunol 1991;88:208-12.
142. Shiner RJ, Nunn AJ, Chung KF, Geddes DM. Randomized double-blind placebo-controlled trial of methotrexate in steroid-dependent asthma. Lancet 1990;336:137-40.
143. Kozarek RA, Patterson DJ, Gelfand MD, Botoman VA, Ball TJ, Wilske KR. Methotrexate induces clinical and histological remission in patients with refractory inflammatory bowel disease. Ann Intern Med 1989;110:353-6.
144. Saadeh C, Urban RS. Azathioprine in the treatment of chronic refractory steroid-dependent asthma [Abstract]. South Med J 1993;86:94-5.
145. Hu SK, Mitcho YL, Oronsky AL, Kerwar SS. Studies on the effect of methotrexate in macrophage function. J Rheumatol 1988;15:206-9.
146. Johnson WJ, Dimartino MJ, Meunier PC, Muirhead KA, Hanna N. Methotrexate inhibits macrophage activation as well as vascular and cellular events in rat adjuvant induced arthritis. J Rheumatol 1988;15:745-9.
147. Feagan BG, Rochon J, Fedorak RN, Irvine EJ, Wild G, Sutherland L, et al. Methotrexate for the treatment of Crohn's disease. N Engl J Med 1995;332:292-7.
148. Lichtiger S, Present DH, Kornbluth A, Gelernt I, Bauer J, Galber G, Michelassi F, Hanauer S. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994;330:1841-5.
149. Alexander AG, Barnes NC, Kay AB, Corrigan CJ. Clinical response to cyclosporin in chronic severe asthma is associated with reduction in serum soluble interleukin-2 receptor concentrations [Abstract]. Eur Respir J 1995;8:574-8.
150. Fukuda T, Asakawa J, Motojima S, Makino S. Cyclosporine A reduces T lymphocyte activity and improves airway hyperresponsiveness in corticosteroid-dependent chronic severe asthma [Abstract]. Ann Allergy Asthma Immunol 1995;75:65-72.
151. Kay AB. Immunosuppressive agents in severe chronic asthma [Review]. Allergy Proc 1994;15:147-50.
152. Alexander AG, Barnes NC, Kay AB. Trial of cyclosporin in corticosteroid-dependent chronic severe asthma [Abstract]. Lancet 1992;339:324-8.
153. Rachmilewitz D, Stamler JS, Karmeli F, Mullins ME, Singel DJ, Loscalzo J, Xavier RJ, Podolsky DK. Peroxynitrite-induced rat colitis - a new model of colonic inflammation. Gastroenterology 1993;105:1681-8.
154. Rachmilewitz D, Stamler JS, Bachwich D, Karmeli F, Ackerman Z, Loscalzo J, Podolsky DK. Enhanced colonic generation and stimulated NO synthase activity in experimental colitis and in active inflammatory bowel disease. Gastroenterology 1993;104:A766.
155. Rachmilewitz D, Karmeli F, Okon E, Bursztyn M. Experimental colitis is ameliorated by inhibition of nitric oxide synthase activity. Gut 1995;37:247-55.
156. Garnier P, Strambu I, Dessanges JF, Dell'Ava J, Lockhart A, Dinh-Xuan AT. Increased level of nitric oxide in the exhaled air from asthmatic patients. Am J Respir Crit Care Med 1994;149:A148.
157. Hamid Q, Springall DR. Riveros-Moreno V, Chanez P, Howarth P, Redington A, Bousquet J, Godard P, Holgate S, Polak JM. Induction of nitric oxide synthase in asthma. Lancet 1993;342:1510-3.